Furthermore, EcN‐GLP‐1 could also combine the advantages of the chassis EcN to modulate the gut microbiota dysbiosis to strengthen its beneficial efficacy in treating PD (Figure 7). The gene discussed is GLP1R; the disease is Parkinson disease.